OBI Pharma Showcases Innovative Pipeline, Platforms, and Technologies at BIO Asia–Taiwan 2025
GlycOBI® and HYPrOBI™ Drive the Advancement of Bispecific, Dual-Payload ADCs

OBI Pharma (4174.TWO) will participate in BIO Asia–Taiwan 2025, taking place in Taipei from July 23 to 27. The company’s engagements will include the Investment Summit, Innovation Forum presentations, and panel discussions. During the event, OBI will showcase its latest research and platform applications in the field of antibody-drug conjugates (ADCs), including its next-generation bispecific, dual-payload ADC candidate targeting cMET x HER3 (BsDpADC).

HOMEWhat’s NewNewsOBI Pharma Showcases Innovative Pipeline, Platforms, and Technologies at BIO Asia–Taiwan 2025 GlycOBI® and HYPrOBI™ Drive the Advancement of Bispecific, Dual-Payload ADCs

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2025.Jun.27

Innovation in Action: OBI Pharma Sharpens Focus on ADC Products, Platforms, and Out-Licensing Integrating Product and Platform Capabilities to Drive Global Collaboration